Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment

Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
——

Segments

By product

See full
AVTX-009$5.13M—

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-—
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$946.18M+1,783%
Enterprise value$921.19M-1,342%
P/S1,892.4×+1,852×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%—
Debt / equity0×0.0×
Current ratio7.7×-14.9×